Boston Scientific Corporation [NYSE: BSX] surged by $0.7 during the normal trading session on Tuesday and reaching a high of $42.06 during the day while it closed the day at $41.40. The company report on December 2, 2021 that Boston Scientific Initiates Trial to Evaluate Industry’s First Modular CRM System.
Trial studying communication between cardiac rhythm management devices aims to expand treatment options for patients who require an ICD.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™ Modular Therapy System. The mCRM System consists of two cardiac rhythm management (CRM) devices intended to work together to coordinate therapy: the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Modular Pacing System (MPS), which is designed to be the first leadless pacemaker capable of delivering both bradycardia pacing support and antitachycardia pacing (ATP).
Boston Scientific Corporation stock has also gained 8.75% of its value over the past 7 days. However, BSX stock has declined by -9.03% in the 3 months of the year. Over the past six months meanwhile, it has lost -2.20% and gained 15.16% year-on date.
The market cap for BSX stock reached $59.20 billion, with 1.42 billion shares outstanding and 1.42 billion shares in the current float. Compared to the average trading volume of 7.10M shares, BSX reached a trading volume of 10074414 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Boston Scientific Corporation [BSX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BSX shares is $51.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BSX stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Needham have made an estimate for Boston Scientific Corporation shares, keeping their opinion on the stock as Hold, with their previous recommendation back on May 26, 2021. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on May 25, 2021, representing the official price target for Boston Scientific Corporation stock. Previously, the target price had yet another raise to $52, while Atlantic Equities analysts kept a Overweight rating on BSX stock.
The Average True Range (ATR) for Boston Scientific Corporation is set at 1.12, with the Price to Sales ratio for BSX stock in the period of the last 12 months amounting to 5.16. The Price to Book ratio for the last quarter was 3.58, with the Price to Cash per share for the same quarter was set at 1.36. Price to Free Cash Flow for BSX in the course of the last twelve months was 36.59 with Quick ratio for the last quarter at 1.20.
BSX stock trade performance evaluation
Boston Scientific Corporation [BSX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.75. With this latest performance, BSX shares dropped by -4.08% in over the last four-week period, additionally sinking by -2.20% over the last 6 months – not to mention a rise of 20.88% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BSX stock in for the last two-week period is set at 52.89, with the RSI for the last a single of trading hit 59.97, and the three-weeks RSI is set at 49.49 for Boston Scientific Corporation [BSX]. The present Moving Average for the last 50 days of trading for this stock 42.24, while it was recorded at 39.86 for the last single week of trading, and 42.35 for the last 200 days.
Boston Scientific Corporation [BSX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Boston Scientific Corporation [BSX] shares currently have an operating margin of +6.06 and a Gross Margin at +56.25. Boston Scientific Corporation’s Net Margin is presently recorded at -0.83.
Return on Total Capital for BSX is now 2.44, given the latest momentum, and Return on Invested Capital for the company is -0.34. Return on Equity for this stock declined to -0.56, with Return on Assets sitting at -0.27. When it comes to the capital structure of this company, Boston Scientific Corporation [BSX] has a Total Debt to Total Equity ratio set at 62.73. Additionally, BSX Total Debt to Total Capital is recorded at 38.55, with Total Debt to Total Assets ending up at 31.24. Long-Term Debt to Equity for the company is recorded at 62.18, with the Long-Term Debt to Total Capital now at 38.21.
Reflecting on the efficiency of the workforce at the company, Boston Scientific Corporation [BSX] managed to generate an average of -$2,158 per employee. Receivables Turnover for the company is 5.72 with a Total Asset Turnover recorded at a value of 0.32.Boston Scientific Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.50.
Earnings per share (EPS) analysis for Boston Scientific Corporation [BSX] stock
With the latest financial reports released by the company, Boston Scientific Corporation posted 0.23/share EPS, while the average EPS was predicted by analysts to be reported at 0.31/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -25.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BSX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Boston Scientific Corporation go to 23.10%.
Boston Scientific Corporation [BSX]: Insider Ownership positions
There are presently around $54,226 million, or 94.30% of BSX stock, in the hands of institutional investors. The top three institutional holders of BSX stocks are: BLACKROCK INC. with ownership of 122,400,261, which is approximately 3.868% of the company’s market cap and around 0.20% of the total institutional ownership; VANGUARD GROUP INC, holding 111,212,803 shares of the stock with an approximate value of $4.6 billion in BSX stocks shares; and FMR LLC, currently with $4.45 billion in BSX stock with ownership of nearly 4.156% of the company’s market capitalization.
Positions in Boston Scientific Corporation stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 416 institutional holders increased their position in Boston Scientific Corporation [NYSE:BSX] by around 68,861,141 shares. Additionally, 350 investors decreased positions by around 52,935,618 shares, while 161 investors held positions by with 1,188,002,178 shares. The mentioned changes placed institutional holdings at 1,309,798,937 shares, according to the latest SEC report filing. BSX stock had 79 new institutional investments in for a total of 13,451,884 shares, while 63 institutional investors sold positions of 5,378,059 shares during the same period.